The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF-kB in estrogen-deficient rats

Background the selective estrogen receptor modulators (serms) raloxifene and tamoxifen are used for the treatment of osteoporosis and cancer,respectively,in women. the impairment of both the atrial natriuretic peptide (anp) cell signaling system and the translocation of nuclear factor-kappa b (nf-kb) to the cell nucleus are associated with detrimental cardiovascular effects and inflammation. the effects of serms on these parameters in the cardiac tissue of estrogen-deficient rats has not been reported. methods we investigated the effects of raloxifene and tamoxifen on anp signaling,p65 nf-kb nuclear translocation,cardiac histology and contractility. female rats were divided into five groups: control (sham),ovariectomized (ovx),ovx-treated 17-β-estradiol (e),ovx-treated raloxifene (rlx) and ovx-treated tamoxifen (tam). the treatments started 21 days after ovariectomy and continued for 14 days. results ovariectomy reduced anp mrna in the left atrium (la),decreased the content of anp protein in the la and in plasma,and increased the level of p65 nf-kb nuclear translocation in the left ventricle. both 17-β-estradiol and serms were able to reverse these alterations,which were induced by the estrogen deficient state. the hemodynamic and cardiac structural parameters analyzed in the present work were not modified by the interventions. conclusions our study demonstrates,for the first time,the additional benefits of raloxifene and tamoxifen in an estrogen-deficient state. these include the normalization of plasmatic and cardiac anp levels and cardiac p65 nf-kb translocation. therefore,these treatments promote cardiovascular protection and may contribute to the prevention of cardiac dysfunction observed long-term in postmenopausal women. © 2017